A first-in-human phase 1a/b trial of LY3484356, an oral selective estrogen receptor (ER) degrader (SERD) in ER+ advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Results from the EMBER study - Jhaveri, K L; Lim, E; Hamilton, E P (J Clin Oncol, 2021)